arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

CollPlant Biotechnologies Ltd

CLGN

$4.05 ▼ -0.12 (-2.76%) at close

9 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

CollPlant Biotechnologies Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $49.4M

Dividend Yield —

Revenue Growth 360.4% ↗

Op. Margin -484.3%

ROIC -149.2% ↘

FCF / Share $-0.77 ↗

Trailing P/E —

Price / Book 8.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.37M

↑ +360.4% —

Net Income Profit after all expenses

$-11.49M

↑ +30.8% —

Operating Margin Operating profit as % of sales

-484.3%

↓ -606.5% 0th

FCF / Share Free cash flow per share

$-0.77

↑ +39.2% —

Long-Term Debt Long-term obligations

$30.00K

↑ +172.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Revenue Growth YoY (%)	360.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4405%)	-95.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1291%)	3565.2% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+44465%)	-98.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1326%)	154.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1836%)	164.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1959%)	-53.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-772%)	—	—
EPS Growth YoY (%)	35.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-133.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	59.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—
Net Income Growth YoY (%)	30.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-136.6% Weak Weak Year-over-year change in net income	58.5% Excellent Excellent Year-over-year change in net income	N/M	N/M	48.3% Excellent Excellent Year-over-year change in net income	-78.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	39.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-289.9% Weak Weak Year-over-year change in free cash flow	75.9% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	—	—	—	—
Revenue CAGR 3Y (%)	99.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-67.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	21.3% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-49.5% Weak Weak Compound annual revenue growth over 3 years	46.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-17.3% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	-26.0% Weak Weak Compound annual revenue growth over 5 years	16.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Operating Margin (%) (%)	-484.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3329%)	—	-68.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-557%)	—	0.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-97%)	-91.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-708%)	-329.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2295%)	-84.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-664%)	—
Profit Margin (%) (%)	-484.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4138%)	—	-64.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-634%)	—	1.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-87%)	-94.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-884%)	-481.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4114%)	-124.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1139%)	—
FCF Margin (%) (%)	-398.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-33.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	—	6.9% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	-79.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-310.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-40.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	4.53x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.33x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Return on Invested Capital (%)	-149.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-101.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	0.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-98.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-147.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-61.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-106.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-92.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	0.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-71.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-188.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1360%)	-123.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-922%)	-24.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-265%)	-52.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-450%)	0.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-96%)	-129.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-960%)	-273.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1921%)	-115.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-869%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Debt to Equity (x)	—	—	—	—	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	0.39x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-36%)
Net Debt (USD)	$-5.59M	$-11.91M	$-26.67M	$-29.65M	$-12.90M	$-3.32M	$-3.79M	$-5.35M	$2.00M
Debt / EBITDA (x)	—	—	—	—	0.30x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Revenue per Share (USD)	$0.19	$0.04	$0.96	$0.03	$1.57	$0.89	—	—	—
Basic EPS, GAAP (USD)	$-0.94	$-1.45	$-0.62	$-1.53	$0.02	$-0.84	—	—	—
Free Cash Flow per Share (USD)	$-0.77	$-1.27	$-0.33	$-1.36	$0.11	$-0.71	—	—	—
Book Value per Share (USD)	$0.47	$1.18	$2.47	$2.89	$4.19	$0.64	$0.72	—	—
Tangible Book Value per Share (USD)	$0.47	$1.16	$2.46	$2.86	$4.17	$0.63	$0.72	—	—
Basic Weighted Avg Shares (shares)	12.20M	11.45M	11.39M	11.03M	9.97M	6.89M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Working Capital (USD)	$4.08M	$10.21M	$24.77M	$28.55M	$42.07M	$2.29M	$1.58M	—	—
LT Debt (USD)	—	—	—	—	$30.00K	$11.00K	—	—	$2.00M
Total Equity (USD)	$6.08M	$13.46M	$28.34M	$32.28M	$45.12M	$4.48M	$4.09M	$5.42M	$5.17M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗
Sales/Revenue/Turnover (USD)	$2.37M	$515.00K	$10.96M	$299.00K	$15.64M	$6.14M	$2.32M	$5.01M	—
Depreciation Expense (USD)	$912.00K	$1.04M	$1.10M	$1.08M	$773.00K	$660.00K	$539.00K	$342.00K	—
Net Income, GAAP (USD)	$-11.49M	$-16.61M	$-7.02M	$-16.93M	$237.00K	$-5.77M	$-11.16M	$-6.25M	—
Operating Cash Flow (USD)	$-9.42M	$-14.09M	$-2.76M	$-13.70M	$2.50M	$-4.45M	$-5.70M	$-1.22M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 9 quarters

CollPlant Biotechnologies Ltd

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CLGN with peers